Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | ATP6V1B2 | P21281 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.36 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | DRD1 | P21728 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093578 | 0.94 | LMNA (0.42) | PDE10AKMT2APOLBDPP4LMNA | |
| SCHEMBL2092397 | 0.92 | PDE10A (0.39) | PDE10AKMT2APOLBDPP4LMNA | |
| SCHEMBL2095944 | 0.86 | SUV39H2 (0.41) | PDE10A | |
| SCHEMBL2094910 | 0.86 | SUV39H2 (0.41) | PDE10A | |
| SCHEMBL2094242 | 0.80 | LMNA (0.43) | PDE10AKMT2ADPP4LMNACYP2C9 | |
| SCHEMBL2094713 | 0.80 | LMNA (0.43) | PDE10AKMT2ADPP4LMNACYP2C9 | |
| SCHEMBL2093152 | 0.78 | SUV39H2 (0.40) | PDE10A | |
| SCHEMBL2093348 | 0.78 | SUV39H2 (0.40) | PDE10A | |
| SCHEMBL1020511 | 0.78 | KMT2A (0.49) | KMT2ADPP4LMNACYP2C9ATP6V1B2 | |
| SCHEMBL2093865 | 0.76 | LMNA (0.55) | KMT2ADPP4LMNACYP2C9ATP6V1B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | PDE10A 1661/4885KMT2A 4682/4885POLB 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.